Table 2.

Characteristics and outcomes of NSCLC patients harboring concurrent EGFR mutations and ALK rearrangements

Pt.EGFR mutationALK FISHEGFR IHCALK IHCErlotinib TherapyOutcome
1L858R+L858R Ab positiveNegativeYesPR; 9 mo
2Del E746_A750+Exon 19 del Ab positiveNegativeYesPR; 5 + mo
3A767_V769dupASV+N.D.PositiveNoN/A

Abbreviations: IHC, immunohistochemistry; PR, partial response; N.D., not done; N/A, not applicable.